Multiple Sclerosis Drugs Market to Exhibit a 6.7% CAGR, Active Government Support Pushes Growth

Multiple Sclerosis Drugs Market Summarized details by key players are Biogen, Pfizer, Inc., Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., and Other players

A non-profit organization called the Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global multiple sclerosis drugs market. The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend by Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Other players

As per a study conducted by the Multiple Sclerosis Foundation, around 2.3 million people across the world live with multiple sclerosis. Considering this, the report predicts the global market for multiple sclerosis drugs to expand at a CAGR of 6.7% between 2018 and 2026. Furthermore, the market was worth US$ 23,460.3 Mn in the year 2018 and is expected to reach US$ 39,289.5 Mn by 2026.

North America Generates the Maximum Revenue Owing to Rising FDA Approvals

North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.

Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from the government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.

Improved distribution network among companies in Asia Pacific is the primary factor responsible for the market’s growth. The market is expected to witness high growth in this region during the forecast region.

Major Table of Content Multiple Sclerosis Drugs Market is;

3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1 Prevalence of Multiple Sclerosis - For Key Countries, 2018
4.2 Regulatory Scenario - For Key Countries
4.3 Patent Snapshot
4.4 New Drug Class Launch
4.5 Pipeline Analysis
4.6 Key Industry Developments - Mergers, Acquisitions, and Partnerships

Get Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Increasing R&D Activities Encourages Immunodulators to Lead

The multiple sclerosis drugs market share is expected to grow in the forecast years. Immunomodulators lead the market over immune suppressants and interferons. The segment covered a share of 67.4% in the global market in 2018. The demand for immunomodulators is increasing as they offer better treatment options for multiple sclerosis. This, coupled with new product launches, is expected to drive the segment by 2026. This will further increase the multiple sclerosis drugs market. In addition to this, immunomodulators are growing rapidly owing to the increasing number of clinical studies and rising research and development (R&D) activities.

As per the route of administration, injection covered the maximum share in the global market in 2018. The wide market approvals and government support are driving the segment’s growth. However, the oral segment is expected to grow considerably in the forecast years.

Mayzent’s FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis. This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market.

As per the report, Biogen, Novartis AG, and F. Hoffmann-La Roche Ltd cover the majority share in the global multiple sclerosis market. Among these, Biogen was the leading player owing to the increasing sales of Tecfidera in 2018. The company entered into strategic partnerships to further extend its distribution network. Following Biogen, Novartis is the second-most leading company in the market. The company developed a drug called Gilenya and owing to its higher demand, Novartis was leading after Biogen.

Some of the other players in the global market are Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Sanofi.

Get Discount at https://www.fortunebusinessinsights.com/enquiry/check-discount/multiple-sclerosis-drugs-market-100386

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd., 308, Supreme Headquarters,, Survey No. 36, Baner,, Pune-Bangalore Highway,, Pune - 411045, Maharashtra, India.
Phone: 4242530390
Website: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Release ID: 88896788